jis
Lv1
60 积分
2021-06-28 加入
-
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
14天前
已完结
-
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
5个月前
已完结
-
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
6个月前
已完结
-
Phase 1 Dose Escalation and Expansion Study of Golidocitinib, a Highly Selective JAK1 Inhibitor, in Relapsed or Refractory Peripheral T Cell Lymphomas
6个月前
已完结
-
Mosunetuzumab-axgb (Lunsumio™)
6个月前
已关闭
-
Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
6个月前
已完结
-
Different expression of DNMT1, PCNA, MCM2, CDT1, EZH2, GMNN and EP300 genes in lymphomagenesis of low vs. high grade lymphoma
6个月前
已完结
-
Use of histone methyltransferase inhibitors in cancer treatment: A systematic review
6个月前
已完结
-
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
9个月前
已完结
-
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
10个月前
已完结